Hunterbrook Media

Full investigation link at www.hntrbrk.com/indorama

The reporting is based on regulatory records, emissions data, dispersion modeling, and interviews with affected residents. It raises broader questions about oversight, transparency, and the human cost of industrial pollution.

Residents near both plants describe chronic odors, flaring, respiratory illness, and cancer diagnoses—alongside a deep reluctance to speak out in communities where petrochemical jobs underpin the local economy.

And at Indorama’s facility in Westlake, Louisiana, company filings show unusually uniform—and potentially unreliable—self-reported pollution data.

Despite the findings, proposed state penalties for the Texas violations total less than $75,000. Indorama reported $15.4 billion in revenue in 2024, making the fines effectively negligible.

Using federal atmospheric dispersion models, a Hunterbrook analysis estimates that a single three-minute leak exposed more than 11,000 residents to ethylene oxide concentrations far above EPA safety thresholds, with the plume extending into Louisiana.

Health data adds context. Jefferson County, where the Indorama facility is located, has the highest breast cancer mortality rate among women under 50 in Texas. Long-term ethylene oxide exposure is associated with elevated cancer risk.

State records show some of these releases were not reported within the legally required 24 hours. In multiple cases, regulators only discovered them during later inspections, more than a year after the fact. Nearby residents Hunterbrook spoke to say they were never notified.

One incident in September 2023 illustrates the scale: a defective tube leaked roughly 1,880 pounds of ethylene oxide in just three minutes—an amount comparable to what some U.S. medical sterilization facilities emit in an entire year.

According to Texas Commission on Environmental Quality records, Indorama emitted several thousand pounds of ethylene oxide and other hazardous pollutants without authorization, following a pattern of leaks and equipment failures.

The facility, located in Port Neches, produces ethylene oxide—an industrial chemical used in plastics and medical sterilization that the EPA classifies as a carcinogen linked to blood and breast cancers.

Hunterbrook Media’s investment affiliate, Hunterbrook Capital, does not have any positions related to this article at the time of publication. Positions may change at any time. Full disclosures at hntrbrk.com

A $3.8B Thai petrochemical giant, Indorama Ventures, pledged to be a responsible neighbor after buying a major southeast Texas plant.

Documents obtained by Hunterbrook Media show the company exposed thousands to carcinogens, violated permits, and hid toxic leaks from regulators

BREAKING: Microsoft Denies Partnership with Richtech Robotics Beep, boop, fraud?

Who knows what Richtech learned about software engineering at the Microsoft Innovation Lab program? But what’s clear is they could teach a course of their own on financial engineering. Read our first piece on $RR at hntrbrk.com/richtech.

This comes months after short seller Capybara Research published a report on September 30, 2025 calling Richtech a "China Hustle" that is "riddled with fraud" and "uninvestable."

Their wild allegations:
x.com/CapybaraShor...

allowing institutional investors to buy stock at a cheaper price than retail. (2/2)

The playbook, in other words, seems to be: Miss your 10-K deadline, limiting your ability to fundraise; announce a collaboration that Microsoft says has "no commercial element;" watch the stock surge 44%; then disclose a private placement the next morning, (1/2)

That means the institution in the private placement may have gotten shares much cheaper than the retail traders bidding it up.

The phrase “under Nasdaq rules” is doing the heavy lifting there. Under those guidelines, "at the market" means at or above the lower of the prior close or trailing 5-day average, which in this case would include the four days before the 40%+ pump.

The morning after the 40% pop, Richtech announced a $38.7 million private placement. Unlike ATM offerings, private placements under Reg D don't require S-3 eligibility. The company called it "priced at-the-market under Nasdaq rules."

For a company burning $20 million/year on $5 million in revenue, losing access to capital markets could be an existential problem. So Richtech needed another way to raise money. Enter: the Microsoft "collaboration."

Missing the deadline may have serious fundraising consequences. To use Form S-3 — which enables shelf offerings and ATM programs — companies need 12 months of timely filings. Richtech's $1 billion shelf registration filed in September may now be frozen until January 2027.

Richtech’s press release came after the company missed its extended 10-K deadline on January 13. Richtech finally filed on January 20 — a week late. No 8-K was filed disclosing a Nasdaq deficiency notice, raising questions about whether one was received and not disclosed.

What’s the reason for the timing of this apparent pump?

We have one idea:

That's … not exactly how Richtech framed it. CEO Wayne Huang touted a "close collaboration" in which "our teams were able to jointly develop and deploy intelligent capabilities." The stock surged more than 40% in a single day.

You can apply here! The application is very quick! aiotlabs.microsoft.com/en

What are the AI Co-Innovation Labs? Microsoft's website describes the program as offering "one-week long complimentary, personalized development sprints" available to "any customers/partners looking to implement Microsoft's AI tools" — including "startups."

"There is no commercial element in this lab engagement." (2/2)

"Richtech participated in an AI Co-Innovation Lab engagement, which is a standard customer engagement focused on exploring and prototyping AI solutions using Microsoft technologies," a Microsoft partnerships representative told Hunterbrook Media. (1/2)

Based on Hunterbrook Media’s reporting, Hunterbrook Capital is short $RR and long a basket of comparable securities at the time of publication. Positions may change at any time. See full disclosures on our website.